Instructions Chondroitin Complex capsules blister No. 60
Composition
active ingredients: glucosamine hydrochloride, chondroitin sodium sulfate;
1 capsule contains glucosamine hydrochloride in terms of 100% substance 500 mg, chondroitin sodium sulfate in terms of 100% substance 400 mg;
excipients: croscarmellose sodium, magnesium stearate.
Dosage form
Capsules.
Main physicochemical properties: hard gelatin capsules with a colorless transparent body and a colorless transparent cap.
The contents of the capsules are white powder with a yellowish tint.
Pharmacotherapeutic group
Medicines used to treat diseases of the musculoskeletal system.
Other medicines used to treat diseases of the musculoskeletal system.
ATX code M09A X.
Pharmacological properties
Pharmacodynamics
Chondroitin® Complex is a combined preparation for stimulating the regeneration of cartilage tissue. The effect of the preparation is due to the components that make up its composition.
Chondroitin sodium sulfate is a high-molecular mucopolysaccharide that participates in the construction of cartilage tissue. Reduces the activity of enzymes that destroy articular cartilage and stimulates its regeneration. In the early stages of the inflammatory process, chondroitin sodium sulfate reduces its activity and thus slows down the degeneration of cartilage tissue. Helps reduce pain, improve joint function, and reduces the need for non-steroidal anti-inflammatory drugs in patients with osteoarthritis of the knee and hip joints.
Glucosamine hydrochloride has chondroprotective properties, reduces the deficiency of glycosamines in the body, participates in the biosynthesis of proteoglycans and hyaluronic acid. Having a tropism for cartilage tissue, glucosamine hydrochloride initiates the process of sulfur fixation during the synthesis of chondroitin sulfate acid. Glucosamine hydrochloride selectively acts on articular cartilage, is a specific substrate and stimulator of the synthesis of hyaluronic acid and proteoglycans, inhibits the formation of superoxide radicals and enzymes that cause damage to cartilage tissue (collagenase and phospholipase), prevents the destructive effect of glucocorticoids on chondrocytes and disruption of the biosynthesis of glycosaminoglycans induced by nonsteroidal anti-inflammatory drugs.
Pharmacokinetics
Absorption. After a single oral administration of the drug in an average therapeutic dose, the maximum concentration of chondroitin sodium sulfate in blood plasma is reached after 3-4 hours, in synovial fluid - after 4-5 hours. The bioavailability of the drug is 13%. Excretion is carried out mainly by the kidneys within 24 hours. 90% of the applied glucosamine is absorbed in the intestine. More than 25% of the dose taken enters the cartilage tissue and synovial membranes of the joints from the blood plasma. In the liver, 70% of the drug is metabolized to urea, carbon dioxide and water.
Indication
Degenerative-dystrophic diseases of the joints and spine: primary and secondary osteoarthritis, shoulder-scapular periarthritis, spinal osteochondrosis, fractures (to accelerate the formation of bone callus).
Contraindication
Hypersensitivity to any of the components of the drug, thrombophlebitis, diabetes mellitus, severe renal/liver dysfunction, phenylketonuria, bleeding tendency, stomach or intestinal ulcer. Do not use in patients with hypersensitivity (allergy) to seafood.
Special safety precautions
Do not exceed the recommended dose. At the beginning of treatment, it is advisable to monitor blood sugar levels in patients with diabetes.
Use with caution in patients with moderate to mild renal and hepatic impairment. Edema and/or water retention have been observed rarely.
The drug should be used with caution in patients with asthma, as such patients may be more prone to developing allergic reactions to glucosamine with possible exacerbation of symptoms of their disease.
Interaction with other medicinal products and other types of interactions
When used in combination, the drug Chondroitin® Complex enhances the absorption of tetracyclines from the gastrointestinal tract and reduces the absorption of semi-synthetic penicillins and chloramphenicol. Chondroitin® Complex can be used together with non-steroidal anti-inflammatory drugs and glucocorticosteroids. Against the background of taking the drug, the need for non-steroidal anti-inflammatory drugs, glucocorticosteroids, as well as analgesics, decreases.
Increased effects of coumarin anticoagulants have been noted. Therefore, it is advisable to monitor coagulation parameters in patients.
When glucosamine and warfarin are used simultaneously, the effect of the latter may be enhanced and bleeding may occur. Therefore, blood coagulation parameters should be monitored during simultaneous use.
Glucosamine may affect the blood concentration of cyclosporine.
The effectiveness of treatment increases when the diet is enriched with vitamins A, C and salts of manganese, magnesium, copper, zinc, and selenium.
Application features
This medicinal product contains sodium compounds. Caution should be exercised when used in patients on a controlled sodium diet.
Ability to influence reaction speed when driving vehicles or other mechanisms
If dizziness or drowsiness, fatigue, or visual disturbances occur during treatment with the drug, you should refrain from driving or operating other mechanisms.
Use during pregnancy or breastfeeding
The drug is contraindicated during pregnancy. Breastfeeding should be discontinued during treatment with the drug.
Method of administration and doses
Chondroitin® Complex is prescribed to adults orally, 1 capsule 3 times a day for the first 3 weeks; then 1 capsule 2 times a day for the next 2-3 months. The course of treatment is usually repeated at 3-month intervals.
Children
The drug is not used in children.
Overdose
Cases of overdose have not been described. Possible increase in side effects. In case of overdose, symptomatic treatment is recommended. If the recommended doses are exceeded, standard supportive measures should be used and a doctor should be consulted.
Adverse reactions
Gastrointestinal: dyspepsia, epigastric pain, nausea, vomiting, flatulence, diarrhea, constipation.
From the nervous system and sensory organs: dizziness, general weakness, drowsiness, headache, insomnia, increased fatigue, visual impairment.
On the part of the immune system: allergic reactions, including hyperemia and skin rashes, itching, urticaria, erythema, dermatitis, maculopapular rashes, eczema, edema, angioedema.
Skin and skin structures: hair loss.
Other adverse reactions: very rarely extrasystoles.
If any adverse reactions occur, you should stop taking the medicine and consult a doctor.
Expiration date
2 years.
Storage conditions
Store in the original packaging at a temperature not exceeding 25 ºС.
Keep out of reach of children.
Packaging
6 capsules in a blister, 10 blisters in a pack.
Vacation category
Without a prescription.
Producer
PJSC "FITOPHARM".
Location of the manufacturer and its business address
Ukraine, 84500, Donetsk region, Bakhmut city, Sibirtseva st., 2.
